Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04964388 · ClinicalTrials.gov registry record · Phase 2
Effect of GLP-1 Receptor Agonists on Trabecular Bone Score
A Phase 2 study, sponsored by University of Mississippi Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04964388 is a Phase 2 study that was terminated before completion, run by University of Mississippi Medical Center. The registered enrollment target is 5 participants.
The verdict
NCT04964388, a Phase 2 study, was terminated before completion, sponsored by University of Mississippi Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study will help determine the effect of Glucagon Like Peptide-1 (GLP-1)receptor agonists on bone strength in postmenopausal women with type 2 diabetes mellitus (T2DM)
Interventions
- DRUG GLP-1 receptor agonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-11-09 |
| Est. Completion | 2023-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04964388
The ClinicalTrials.gov registry entry for NCT04964388 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi Medical Center, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GLP-1 receptor agonist is the first listed.
NCT04964388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04964388 about?
NCT04964388 is a clinical study titled "Effect of GLP-1 Receptor Agonists on Trabecular Bone Score". This study will help determine the effect of Glucagon Like Peptide-1 (GLP-1)receptor agonists on bone strength in postmenopausal women with type 2 diabetes mellitus (T2DM)
What is the current status of trial NCT04964388?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2021-11-09. Estimated completion is 2023-07-01.
What interventions are being tested in trial NCT04964388?
The interventions under investigation include: GLP-1 receptor agonist (DRUG).
Who is sponsoring clinical trial NCT04964388?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.